What is the current stock price of Genelux Corporation (GNLX)?

As of the latest market data, Genelux Corporation (GNLX) is trading at $2.54. The stock has seen a loss of -0.78% today.

Does Genelux Corporation (GNLX) pay a dividend?

Based on current data, Genelux Corporation does not have a confirmed active dividend policy.

What is the market cap of Genelux Corporation?

The current market capitalization of Genelux Corporation (GNLX) is approximately unavailable.

GNLX

Genelux Corporation·Healthcare

2.54

0.781%(−0.02)

Market Closed

2.89

13.780%(+0.35)

After Hours

Last Updated: — ET

52W L: $2.2552W H: $8.54

GNLX NEWS

globenewswire.com

Mar 19

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 --

globenewswire.com

Jan 12

Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners

WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT.

Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2023-01-26

Beta

0.46

Websitewww.genelux.com↗